Knowledge graph · Drug
Lutetium (177lu) Vipivotide Tetraxetan
other
- Identifier
- CI-DRUG-00000753
- Entity page
- /drug/lutetium-177lu-vipivotide-tetraxetan ↗
- Edges
- 67
- Neighbours
- 16 cancers1 genes10 trials2 approvals
- Drawn
- 29 of 29 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Lutetium (177lu) Vipivotide Tetraxetan approved for …APPROVED_FORderived2 of 2 | ||||||||
| → approved for | EMA · EU · 2022Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. EMA (EU) · approved · 2022-12-09 · Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for … | — | approved | not mapped | 1 | Regulatory | ema | open ↗ |